Multiple Sclerosis

In a longterm condition like multiple sclerosis finding the proper treatment option can often be a difficult task. A medication was recently approved to help patients who have struggled to find that help in the past.

Proper nutrition can benefit everyone but keeping a healthy diet can be especially important for patients with multiple sclerosis.

While it is a rare condition and no medications have been approved for its treatment patients with neuromyelitis optica can get the help they need if doctors know what they are looking for.

As more is learned about the gut microbiome researchers are finding new ways to apply it to other fields of medicine. A recent study looked at how it can affect multiple sclerosis and what role it can have in future treatment options.

Increased awareness of risk factors and symptoms among primary care physicians, prompt referral of suspected cases to specialists, and a growing armamentarium of disease-modifying drugs lead to better prognosis for patients.

A presentation at the 2015 CMSC annual meeting made the case that focal, specific, subacute, neurologic problems in otherwise healthy adults should be diligently followed, and MRI can be an useful tool in differential diagnosis.

Recent studies have revealed clues to the role played by the gut microbiome in a variety of diseases and conditions. Now researchers are looking at whether aberrant immune responses triggered by disruptions in the gut microbiome are to blame for multiple sclerosis.

Key features in the clinical examination of interstitial lung diseases and their management are the focus of a new clinical review. Highlights here.

A drug normally used to treat hypertension reduced the symptoms of multiple sclerosis in mice models of the disease.

Mouse models of multiple sclerosis were able to halt disease progression after targeting the nucleus of inflammatory cells.

Researchers in the US and Sweden recently reported that coffee consumption in the years prior to multiple sclerosis symptom onset has a significant protective effect.

Drugs that activate brain stem cell production may be able to reverse multiple sclerosis, according to research published in Nature.

A recent study conducted of patients with multiple sclerosis showed that a change could be coming in the field. Just as patients said they wanted to be more involved in their choice of treatment options, their healthcare professionals said they encouraged feedback from the patients.

As part of the overall picture of multiple sclerosis treatment optic neuritis is one of the early stages of the condition. The studies looked at sodium channels that show promise for future multiple sclerosis patients even if it is not in the field.

Medications in general can take a long time to develop. Depending on the condition they treat that process can be even longer as more questions have to be answered before they can be introduced to the field. This is particularly true of multiple sclerosis treatments.

As a treatment for multiple sclerosis teriflunomide has shown benefits over a long development period and has proven effective in the treatment of patients with the relapsing-remitting form of the condition.

For as many drugs and therapies as there are for multiple sclerosis some are more aggressive than others. Alemtuzumab's approach is more on the aggressive end of the spectrum.

Progress in treating multiple sclerosis (MS) has come at a price-rapidly escalating drug costs, according to an opinion piece analysis published online today in Neurology. The increases outstrip drug-price inflation by 5 to 7 times. When it comes to pharma pricing, the rules of classic economics seem not to apply, the report concludes, urging a protest.

Doctors treating patients with pediatric multiple sclerosis often turn to the same treatments as adult patients. While there are some unique characteristics and more work is being done in the field, these seem to give the best hope of maintaining a high quality of life for the young patients.

Getting a proper diagnosis for pediatric multiple sclerosis is not an easy task and requires a partnership between doctors, patients and their families.

A lot of attention in the field of multiple sclerosis is being dedicated to neuroprotection and remyelination. Whether these can someday lead to more effective treatments remains to be seen but there is optimism among doctors and researchers alike.

Multiple sclerosis, especially in the relapsing form poses a variety of challenges for patient care. Keeping that in mind, the development of medications for the condition also take time to progress.

Developing drugs for conditions like multiple sclerosis takes a long time and a considerable amount of research. How the drugs are used, and changed is a delicate process undertaken between doctors and their patients over the course of the disease.

Chronic conditions like multiple sclerosis require constant monitoring by doctors and patients, As time goes on medication and treatment options may need to be changed. Tecfidera, one popular treatment option has become a popular choice in patient care.

Natalizumab, a drug typically used to treat multiple sclerosis and Crohn's disease, has been shown to be effective in treating animal models of HIV.

Stem cell transplants significantly reduce multiple sclerosis disease activity better than mitoxantrone, according to research published in Neurology.

You can tell a lot about a person by the way they walk, the way they sit, and the way they conduct themselves in general. Recent research has also shown that signs of potential health issues can be seen when watching a person move.

Patients with multiple sclerosis (MS) often have sensitivity to heat that worsens their symptoms. In earlier studies with MS patients, a device system that cools body temperature by chilling one palm proved useful in helping them walk faster and longer. But patients need to be motivated to use it successfully.

Although the number of pediatric patients with multiple sclerosis has increased over the years, researchers recently revealed one of the first studies to offer population-based information.

New evidence has made it easier to differentiate between multiple sclerosis and vanishing white matter disease, conditions that can show considerable similarities.